CPL Biologicals, a joint venture of Cadila Pharmaceuticals Ltd. (Ahmendabad, India) and Novavax, Inc. (Rockville, MD), has completed construction of its vaccine facility in Dholka, India.
CPL Biologicals (CPLB), a joint venture of Cadila Pharmaceuticals Ltd. (Ahmendabad, India) and Novavax, Inc. (Rockville, MD), has completed construction of its vaccine facility in Dholka, India. CPLB will commence equipment and installation validation this month so the facility will conform to global standards for production of vaccines for human use.
The new facility uses state-of-the-art equipment for the potential production of up to 60 million doses of vaccines every year. The facility plans to produce seasonal and pandemic flu vaccines based on Novavax's virus-like particle (VLP) technology that enables the rapid development and production of vaccines without the use of live virus.
In addition to vaccine production, CPLB also is focused on the development, manufacture, and sale of biosimilars and diagnostic kits.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.